Skip to main content

Table 1 Cardiac function assessed by echocardiography at 2 weeks after BO

From: Vidarabine, an anti-herpes agent, prevents occlusal-disharmony-induced cardiac dysfunction in mice

  Control BO V BO + V
n 6 6 7 6
IVSTd 0.57 ± 0.06 0.53 ± 0.08 0.59 ± 0.08 0.51 ± 0.05
LVSTs 0.95 ± 0.07 0.86 ± 0.03 0.92 ± 0.07 0.84 ± 0.04*
LVEDV 0.21 ± 0.03 0.21 ± 0.01 0.21 ± 0.03 0.19 ± 0.03
CO 57 ± 8.6 54 ± 4.5 60 ± 8.9 48 ± 9.6
HR 468 ± 57 468 ± 20 473 ± 62 434 ± 73
LVIDd 4.4 ± 0.2 4.4 ± 0.1 4.4 ± 0.3 4.2 ± 0.2
LVIDs 3.0 ± 0.1 3.2 ± 0.1 2.9 ± 0.4 2.9 ± 0.2
ESV 0.07 ± 0.009 0.08 ± 0.009 0.07 ± 0.02 0.06 ± 0.01#
EF 68 ± 1.1 61 ± 3.0*** 67 ± 2.3 66 ± 1.4##
LVPWTd 0.56 ± 0.03 0.54 ± 0.04 0.59 ± 0.04 0.56 ± 0.04
LVPWTs 0.91 ± 0.06 0.86 ± 0.06 0.91 ± 0.07 0.84 ± 0.09
SV 0.14 ± 0.02 0.13 ± 0.01 0.14 ± 0.02 0.12 ± 0.02
%FS 33 ± 0.8 28 ± 1.9*** 32 ± 1.5 31 ± 1.0##
  1. IVSTd (mm): interventricular septum thickness at end-diastole, LVSTs (mm): interventricular septum thickness at end-systole, LVEDV (mL): left ventricular end-diastolic volume, CO (mL/min): cardiac output, LVIDd (mm): left ventricular internal dimension at end-diastole, LVIDs (mm): left ventricular internal dimension at end-diastole, ESV (mL): left ventricular end-systolic volume, EF (%): ejection fraction, LVPWTd (mm): left ventricular posterior wall thickness at end-diastole, LVPWTs (mm): left ventricular posterior wall thickness at end-diastole, SV (mL): stroke volume, %FS (%): % fractional shortening
  2. ***P < 0.001 vs. Control
  3. ##P < 0.05 vs. BO
  4. #P < 0.05 vs. BO